Modern solution to the problems of hair growth and loss

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To evaluate the therapeutic efficacy of Floema® Complex in correcting androgenetic alopecia in women Subject and methods. The investigation involved 30 female patients diagnosed with androgenetic alopecia, who were divided into 2 groups according to therapy: 1) a control group of 15 patients who received mesoscooter therapy; 2) a study group of 15 patients who had topical treatment with Floema® Complex-based lotion applied to the scalp with one 1-ml pipette per night, as well as mesoscooter therapy. Therapy in both groups was performed for 3 months. Before and after treatment, all the patients underwent trichoscopy and phototrichogram using a special software and hardware FotoFinder system. To assess clinical presentations over time, survey scalp photography was done before and 3 months after therapy. Results. The study group patients were observed to have a more pronounced effect of treatment according to the following indicators: an increase in hair density in the parietal region from 191.0 (181.0-201.0) to 221.0 (207.0-228.0) (p=0.009), a decrease in the percent of telogen hair from 22.0 (16.0-33.0) to 14.0 (9.0-19.0) (p=0.116), and that in the percent of vellus hair from 23.0 (16.0 28.0) to 13.0 (11.0-16.0) (p=0.081); the control group had no significant positive changes in the condition of hair, as shown by the results of phototrichograms. Conclusion. A clinical study showed that Floema® Complex was highly effective in treating androgenetic alopecia in women.

全文:

受限制的访问

作者简介

S. Ledentsova

Consultative and diagnostic center of Saint Petersburg State Pediatric Medical University Ministry of Health of Russia; OOO “SOGAZ” International Medical Center

编辑信件的主要联系方式.
Email: led23@mail.ru
Saint Petersburg

参考

  1. Самцов А.В., Божченко А.А. Андрогенетическая алопеция: некоторые аспекты нарушений тканевого метаболизма сально-волосяного аппарата и современные подходы к их коррекции. Клиническая дерматология и венерология. 2007; 4: 4-8.
  2. Weitz R. Rapunzel’s Daughters: What Women’s Hair Tells Us About Women’s Lives. New York: Farrar, Straus and Giroux, 2004.
  3. Hunt N., McHale S. The psychological impact of alopecia. BMJ. 2005; 331 (7522): 951-3. doi: 10.1136/bmj.331.7522.951
  4. Hunt N., McHale S. Reported experiences of persons with alopecia areata. J Loss Trauma. 2005; 10: 33-50. doi: 10.1080/153250200490890633
  5. Hunt N., McHale S. Understanding alopecia. London: Sheldon, 2004.
  6. Gan D.C., Sinclair R.D. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005; 10 (3): 184-9. doi: 10.1111/j.1087-0024.2005.10102.x
  7. Harrison S., Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009; 76 (6): 361-7. doi: 10.3949/ccjm.76a.08080
  8. Werner B., Mulinari-Brenner F. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata - part II. An Bras Dermatol. 2012; 87 (6): 884-90. doi: 10.1590/s0365-05962012000600010
  9. Price V.H. Treatment of hair loss. N Engl J Med. 1999; 341 (13): 964-73. doi: 10.1056/NEJM199909233411307
  10. Dinh Q.Q., Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007; 2 (2): 189-99.
  11. Heilmann S., Kiefer A.K., Fricker N. et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013; 133 (6): 1489-96. doi: 10.1038/jid.2013.43
  12. Аравийская Е. Р., Михеев Г. Н., Мошкалова И. А. и др. Облысение. Дифференциальный диагноз. Методы терапии. Под ред. Е.В. Соколовского. СПб: СОТИС, 2003; 176 с.
  13. Headington J.T. Telogen effluvium. New concepts and review. Arch Dermatol. 1993; 129 (3): 356-63. doi: 10.1001/archderm.129.3.356
  14. Randall V.A. Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev Biol. 2007; 18 (2): 274-85. doi: 10.1016/j.semcdb.2007.02.004
  15. Kaufman K.D. Androgens and alopecia. Mol Cell Endocrinol. 2002; 198 (1-2): 89-95. doi: 10.1016/s0303-7207(02)00372-6
  16. Messenger A.G., de Berker D.A.R., Sinclair R.D. Chapter 66. Disorders of Hair. In: Rook’s Textbook of Dermatology. 8th ed. Oxford, UK: Blackwell Science Publications, 2010; 66.1-66.16.
  17. Hebert J.M., Rosenquist T., Gotz J. et al. FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell. 1994; 78 (6): 1017-25. doi: 10.1016/0092-8674(94)90276-3
  18. Botchkarev V.A., Kishimoto J. Molecular control of epithelial-mesenchymal interactions during hair follicle cycling. J Investig Dermatol Symp Proc. 2003; 8 (1): 46-55. doi: 10.1046/j.1523-1747.2003.12171.x
  19. Chen C.C., Chuong C.M. Multi-layered environmental regulation on the homeostasis of stem cells: the saga of hair growth and alopecia. J Dermatol Sci. 2012; 66 (1): 3-11. doi: 10.1016/j.jdermsci.2012.02.007
  20. Takakura N., Yoshida H., Kunisada T. et al. Involvement of platelet-derived growth factor receptor-alpha in hair canal formation. J Invest Dermatol. 1996; 107 (5): 770-7. doi: 10.1111/1523-1747.ep12371802
  21. Yano K., Oura H. Angiogenesis by VEGF controls hair growth and follicle size. Cell Technol. 2001; 20: 852-3.
  22. Kanti V., Messenger A., Dobos G. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018; 32 (1): 11-22. doi: 10.1111/jdv.14624
  23. Paus R., Olsen E.A., Messenger A.G. Hair growth disorders. In: Wolff K., Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller As, Leffell D.J., eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. USA: The McGraw-Hill Companies Inc, 2008; 753-77.
  24. Jain R., De-Eknamkul W. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin Ther Targets. 2014; 18 (7): 787-806. doi: 10.1517/14728222.2014.922956
  25. Bohlen P., Esch F., Baird A. et al. Acidic fibroblast growth factor (FGF) from bovine brain: amino-terminal sequence and comparison with basic FGF. EMBO J. 1985; 4 (8): 1951-6. doi: 10.1002/j.1460-2075.1985.tb03876.x
  26. Kawano M., Komi-Kuramochi A., Asada M. et al.Comprehensive analysis of FGF and FGFR expression in skin: FGF18 is highly expressed in hair follicles and capable of inducing anagen from telogen stage hair follicles. J Invest Dermatol. 2005; 124 (5): 877-85. doi: 10.1111/j.0022-202X.2005.23693.x
  27. Kimura-Ueki M., Oda Y., Oki J. et al. Hair cycle resting phase is regulated by cyclic epithelial FGF18 signaling. J Invest Dermatol. 2012; 132 (5): 1338-45. doi: 10.1038/jid.2011.490
  28. Lupo M.P., Cole A.L. Cosmeceutical peptides. Dermatol Ther. 2007; 20 (5): 343-9. doi: 10.1111/j.1529-8019.2007.00148.x
  29. Хавинсон В.Х., Кветная Т.В. Регуляторные пептиды и гомеостаз. Росс хим журн. 2005; XLIX (1): 112-7.
  30. Kang Y.A., Na J.I., Choi H.R. et al. Novel anti-inflammatory peptides as cosmeceutical peptides. Peptides. 2011; 32 (10): 2134-6. doi: 10.1016/j.peptides.2011.08.017

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Hair density index in Groups 1 and 2 patients before and after therapy cycle

下载 (103KB)
索引源数据
3. Fig. 2. Scalp photofixation before and 3 months after therapy with Floema® Complex in a female patient from Group 2: а – the left temporal region before treatment; б – the left temporal region after treatment; в – the right temporal region before treatment; г – the right temporal region after treatment; д – the middle parted hair before treatment; е – the middle parted hair after treatment

下载 (1MB)
索引源数据
4. Fig. 3. Parietal zone phototrichogram before (а) and 3 months after (б) therapy with Floema® Complex in a female patient from Group 2 (explanations in the text)

下载 (622KB)
索引源数据
5. Fig. 4. Comparative HADS results in Groups 1 and 2 before and after treatment

下载 (98KB)
索引源数据
##common.cookie##